MED-X (MXRX) Files Fifth S-1/A for Its 16.25 Million Share Nasdaq IPO

As seen on the 24/7 Wall St. homepage on November 19, 2026.

IPO TERMS REVISED
MED-X, INC. MXRX · Nasdaq
16,248,842 shares

Fifth S-1/A keeps the 16.25 million share Nasdaq deal in motion

A fifth amendment means MED-X is still reworking terms on a Nasdaq listing that would float 16.25 million shares, with Maxim Group running the book. Pricing terms remain unset, so the dilution math is the only number investors can anchor to right now.

Continue ReadingShow less

MED-X has now filed five amendments to its S-1 registration statement as it works toward a Nasdaq listing, with Maxim Group running the book on the deal. The repeated amendments signal that the company and its underwriter are still negotiating the final structure of the offering, with no imminent pricing date in sight.

The share count on the table stands at 16,248,842, and that figure is currently the only concrete number investors have to work with. Because pricing terms remain unset, there is no way yet to calculate a market capitalization, a per-share range, or total proceeds, leaving dilution as the sole anchor for anyone sizing up the deal.

Sponsored

For prospective investors, the fifth amendment extends the period of uncertainty. Each new filing keeps the registration active and signals continued intent to list, but it also means the company has not yet satisfied whatever conditions, comments, or structural questions have prompted prior revisions.

The SEC filing itself is publicly available and represents the primary document for anyone tracking how the offering terms evolve with each successive amendment. Until a price range is established and disclosed, the deal remains in motion without a clear finish line.

Mentioned: MXRX